DelveInsight’s “Gastroparesis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroparesis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroparesis Market Forecast

Some of the key facts of the Gastroparesis Market Report: 

• The Gastroparesis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• There were approximately 34,429,813 prevalent cases of gastroparesis in the 7MM overall in 2021. The number of cases of gastroparesis in the 7MM is anticipated to rise from 2019 to 2032.
• According to estimations, the United States had the highest frequency of gastroparesis with 13,403,120 cases in 2021, and that number is anticipated to climb by 2032
• It has been found that mild instances are more common than moderate-to-severe ones. Approximately 8,041,872 mild cases, or 60% of the patient population with the common gastroparesis, were found in the United States in 2021
• Germany had the highest prevalence of gastroparesis among the EU4 and the UK in 2021, followed by Spain and Italy. However, with 2,026,066 cases, the United Kingdom had the lowest prevalence of gastroparesis in 2021. Additionally, there were 5,855,411 gastroparesis frequent cases in Japan in 2021
• Key Gastroparesis Companies: Vanda Pharmaceuticals, Processa Pharma, Dr. Falk Pharma GmbH, Theravance Biopharma, PTC Therapeutics, CinDome Pharma, Inc., GlaxoSmithKline, Chugai Pharma USA, Neurogastrx, Inc., Targacept Inc, Takeda, Eli Lilly and Company, Forest Laboratories, and others
• Key Gastroparesis Therapies: Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, CIN-102, Camicinal, GM-611, NG101, TC-6499, TAK-954, tadalafil, Itopride, and others
• The Gastroparesis epidemiology based on gender analyzed that Gastroparesis cases were higher in females in comparison to males, in all the 7MM countries
• The Gastroparesis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroparesis pipeline products will significantly revolutionize the Gastroparesis market dynamics.

Gastroparesis Overview

The digestive disorder known as gastroparesis, which translates to “stomach paralysis,” is characterised by delayed gastric emptying of solid food in the absence of mechanical obstruction of the stomach. This leads to the classic symptoms of early satiety, postprandial fullness, nausea, vomiting, belching, and bloating.

Get a Free sample for the Gastroparesis Market Report 

https://www.delveinsight.com/report-store/gastroparesis-market

Gastroparesis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroparesis Epidemiology Segmentation:

The Gastroparesis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Gastroparesis
• Prevalent Cases of Gastroparesis by severity
• Gender-specific Prevalence of Gastroparesis
• Diagnosed Cases of Episodic and Chronic Gastroparesis

Download the report to understand which factors are driving Gastroparesis epidemiology trends @ Gastroparesis Epidemiology Forecast

Gastroparesis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroparesis market or expected to get launched during the study period. The analysis covers Gastroparesis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroparesis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroparesis Therapies and Key Companies

• Tradipitant: Vanda Pharmaceuticals
• PCS12852: Processa Pharma
• Naronapride: Dr. Falk Pharma GmbH
• velusetrag: Theravance Biopharma
• CNSA-001: PTC Therapeutics
• Velusetrag: Theravance Biopharma
• CIN-102: CinDome Pharma, Inc.
• Camicinal: GlaxoSmithKline
• GM-611: Chugai Pharma USA
• NG101: Neurogastrx, Inc.
• TC-6499: Targacept Inc
• TAK-954: Takeda
• tadalafil: Eli Lilly and Company
• Itopride: Forest Laboratories

Discover more about therapies set to grab major Gastroparesis market share @ Gastroparesis Treatment Market

Scope of the Gastroparesis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastroparesis Companies: Vanda Pharmaceuticals, Processa Pharma, Dr. Falk Pharma GmbH, Theravance Biopharma, PTC Therapeutics, CinDome Pharma, Inc., GlaxoSmithKline, Chugai Pharma USA, Neurogastrx, Inc., Targacept Inc, Takeda, Eli Lilly and Company, Forest Laboratories, and others
• Key Gastroparesis Therapies: Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, CIN-102, Camicinal, GM-611, NG101, TC-6499, TAK-954, tadalafil, Itopride, and others
• Gastroparesis Therapeutic Assessment: Gastroparesis current marketed and Gastroparesis emerging therapies
• Gastroparesis Market Dynamics: Gastroparesis market drivers and Gastroparesis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Gastroparesis Unmet Needs, KOL’s views, Analyst’s views, Gastroparesis Market Access and Reimbursement 

To know more about Gastroparesis companies working in the treatment market, visit @ Gastroparesis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Gastroparesis Market Report Introduction

2. Executive Summary for Gastroparesis

3. SWOT analysis of Gastroparesis

4. Gastroparesis Patient Share (%) Overview at a Glance

5. Gastroparesis Market Overview at a Glance

6. Gastroparesis Disease Background and Overview

7. Gastroparesis Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroparesis 

9. Gastroparesis Current Treatment and Medical Practices

10. Gastroparesis Unmet Needs

11. Gastroparesis Emerging Therapies

12. Gastroparesis Market Outlook

13. Country-Wise Gastroparesis Market Analysis (2019–2032)

14. Gastroparesis Market Access and Reimbursement of Therapies

15. Gastroparesis Market Drivers

16. Gastroparesis Market Barriers

17.  Gastroparesis Appendix

18. Gastroparesis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services